Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC

被引：0
|
作者：
Waterhouse, D. M. [1 ]
Rothschild, S. [2 ]
Dooms, C. [3 ]
Mennecier, B. [4 ]
Bozorgmehr, F. [5 ]
Majem, M. [6 ]
van den Heuvel, M. [7 ]
Linardou, H. [8 ,9 ]
Chul-Cho, B. [10 ]
Roberts-Thomson, R. [11 ]
Okamoto, I. [12 ]
Blais, N. [13 ]
Schvartsman, G. [14 ]
Holmskov, K. [15 ]
Chmielewska, I. [16 ]
Forster, M. [17 ]
Stollenwerk, B. [18 ]
Obiozor, C. C. [19 ]
Wang, Y. [19 ]
Novello, S. [20 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Univ Basel, Ctr Comprehens Canc, Med Oncol, Basel, Switzerland
[3] Univ Hosp, Dept Resp Dis, Leuven, Belgium
[4] Univ Hosp Strasbourg, Pulmonol Unit, Strasbourg, France
[5] Univ Hosp Heidelberg, Dept Thorac Oncol, Thoraxklin, Heidelberg, Germany
[6] Hosp Santa Creu & Sant Pau, Med Oncol, Serv Oncol Med, Barcelona, Spain
[7] Radboud Univ Nijmegen, Dept Resp Dis, Med Ctr, Nijmegen, Netherlands
[8] Metropolitan Hosp, Oncol Dept 4, Athens, Greece
[9] Metropolitan Hosp, Comprehens Clin Trials Ctr, Athens, Greece
[10] Yonsei Univ, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr,Coll Med, Seoul, South Korea
[11] Queen Elizabeth Hosp, Dept Med Oncol, Woodville, SA, Australia
[12] Kyushu Univ Hosp, Fukuoka, Japan
[13] Ctr Hosp Univ Montreal, Dept Med, Montreal, PQ, Canada
[14] Hosp Israelita Albert Einstein, Ctr Oncol & Hematol Einstein Famila Dayan Daycova, Sao Paulo, Brazil
[15] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[16] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, Lublin, Poland
[17] UCL, Canc Inst, London, England
[18] Amgen Europe GmbH, Rotkreuz, Switzerland
[19] Amgen Inc, Thousand Oaks, CA USA
[20] Univ Torino, Dept Oncol, San Luigi Hosp, Turin, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4O
引用
收藏
页码：S37 / S38
页数：2
相关论文
共 50 条
  • [21] CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Font, E. F.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S29 - S29
  • [22] Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial
    Li, Bob T.
    Clarke, Jeffrey Melson
    Felip, Enriqueta
    Ruffinelli, Jose Carlos
    Garrido, Pilar
    Zugazagoitia, Jon
    Goldberg, Sarah B.
    Ramalingam, Suresh S.
    Victoria, Ivan
    Puri, Sonam
    Gandara, David R.
    Kormany, William
    Edmonds, Sophie
    Palmer, Kerry
    Gupta, Ravi G.
    Govindan, Ramaswamy
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)
    Dingemans, Anne-Marie C.
    Syrigos, Konstantinos
    Livi, Lorenzo
    Paulus, Astrid
    Kim, Sang-We
    Chen, Yuanbin
    Felip, Enriqueta
    Griesinger, Frank
    Ohashi, Kadoaki
    Zalcman, Gerard
    Hughes, Brett Gordon Maxwell
    Sorensen, Jens Benn
    Blais, Normand
    Ferreira, Carlos G. M.
    Lindsay, Colin R.
    Dziadziuszko, Rafal
    Ward, Patrick J.
    Obiozor, Cynthia Chinedu
    Wang, Yang
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA9016 - LBA9016
  • [24] Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis
    Li, B.
    Skoulidis, F.
    Falchook, G.
    Sacher, A.
    Velcheti, V.
    Dy, G.
    Price, T.
    Borghaei, H.
    Schuler, M.
    Kato, T.
    Takahashi, T.
    Spira, A.
    Ramalingam, S.
    Besse, B.
    Barlesi, F.
    Tran, Q.
    Henary, H.
    Ngarmchamnanrith, G.
    Govindan, R.
    Wolf, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S61 - S61
  • [25] Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)
    Dingemans, Anne-Marie C.
    Syrigos, Konstantinos
    Livi, Lorenzo
    Paulus, Astrid
    Kim, Sang-We
    Chen, Yuanbin
    Felip, Enriqueta
    Griesinger, Frank
    Ohashi, Kadoaki
    Zalcman, Gerard
    Hughes, Brett Gordon Maxwell
    Sorensen, Jens Benn
    Blais, Normand
    Ferreira, Carlos G. M.
    Lindsay, Colin R.
    Dziadziuszko, Rafal
    Ward, Patrick J.
    Obiozor, Cynthia Chinedu
    Wang, Yang
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [26] Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
    Hochmair, Maximilian J.
    Vermaelen, Karim
    Mountzios, Giannis
    Carcereny, Enric
    Dooms, Christophe
    Lee, Se-Hoon
    Morocz, Eva
    Kato, Terufumi
    Ciuleanu, Tudor-Eliade
    Dy, Grace K.
    Parente, Barbara
    O'Byrne, Kenneth J.
    Chu, Quincy S.
    De Castro Junior, Gilberto
    Girard, Nicolas
    Snyder, Wendy
    Tran, Qui
    Kormany, William
    Houk, Brett
    Mehta, Bhakti
    Curioni-Fontecedro, Alessandra
    EUROPEAN JOURNAL OF CANCER, 2024, 208
  • [27] Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)
    Barlesi, Fabrice
    Felip, Enriqueta
    Popat, Sanjay
    Solomon, Benjamin J.
    Wolf, Juergen
    Li, Bob T.
    Wu, Yi-Long
    Kerr, Keith
    Akamatsu, Hiroaki
    Camidge, David Ross
    Gupta, Ravi G.
    Meloni, Alison
    Dai, Tian
    Borghaei, Hossein
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C-mutated metastatic colorectal cancer (CodeBreaK 301).
    Kim, Tae Won
    Price, Timothy
    Grasselli, Julieta
    Masuishi, Toshiki
    Kwok, Gin Wai
    Yalcin, Suayib
    Obiozor, Cynthia Chinedu
    Chan, Emily
    Gokani, Priya
    Sunakawa, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS326 - TPS326
  • [29] Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100
    Ramalingam, S.
    Skoulidis, F.
    Govindan, R.
    Velcheti, V.
    Li, B.
    Besse, B.
    Dy, G.
    Kim, D.
    Schuler, M.
    Vincent, M.
    Wilson, F.
    Park, J.
    Gutierrez, J.
    Tran, Q.
    Jones, S.
    Wolf, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1123 - S1123
  • [30] Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C-Mutated NSCLC
    Zhou, Katherine I.
    Lin, Chenyu
    Tseng, Chin-Lin
    Ramnath, Nithya
    Dowell, Jonathan E.
    Kelley, Michael J.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (05):
12345